This article has Open Peer Review reports available.
Cigarette smoke increases cardiomyocyte ceramide accumulation and inhibits mitochondrial respiration
© Tippetts et al.; licensee BioMed Central Ltd. 2014
Received: 6 October 2014
Accepted: 17 November 2014
Published: 22 November 2014
Cigarette smoking is a common and lethal worldwide habit, with considerable mortality stemming from its deleterious effects on heart function. While current theories posit altered blood lipids and fibrinogen metabolism as likely mediators, none have explored the role of the sphingolipid ceramide in exacerbating heart function with smoke exposure. Ceramide production is a consequence of cigarette smoke in the lung, and considering ceramide’s harmful effects on mitochondrial function, we sought to elucidate the role of ceramide in mediating smoke-induced altered heart mitochondrial respiration.
Lung cells (A549) were exposed to cigarette smoke extract (CSE) and heart cells (H9C2) were exposed to the lung-cell conditioned medium. Adult male mice were exposed sidestream cigarette smoke for 8 wk with dietary intervention and ceramide inhibition. Ceramides and heart cell or myocardial mitochondrial respiration were determined.
Lung cell cultures revealed a robust response to cigarette smoke extract in both production and secretion of ceramides. Heart cells incubated with lung-cell conditioned medium revealed a pronounced inhibition of myocardial mitochondrial respiration, though this effect was mitigated with ceramide inhibition via myriocin. In vivo, heart ceramides increased roughly 600% in adult mice with long-term sidestream cigarette smoke exposure. This resulted in a significant ceramide-dependent reduction in left myocardial mitochondrial respiration, as heart mitochondria from the mice exposed to both smoke and myriocin injections respired normally.
These results suggest ceramide to be an important mediator of altered myocardial mitochondrial function with cigarette smoke exposure. Thus, anti-ceramide therapies might be considered in the future to protect heart mitochondrial function with smoke exposure.
Cigarette smoke exposure is the leading cause of preventable deaths worldwide  and is among the top ten contributors to the worldwide health burden . Despite concerted social efforts to reduce smoking prevalence, current trends suggest the number of smokers will increase worldwide [3, 4]. Moreover, cigarette smoke is a common inhaled toxin—almost half of the U.S. population is regularly exposed to cigarette smoke [5, 6] and approximately 20% of young children live with someone who smokes in the home . Much of smoking’s health burden stems from the increased risk of chronic diseases like cancer, emphysema, and cardiovascular disease [8, 9], including cardiomyopathy—a deterioration of heart muscle.
Cardiomyocytes are highly oxidative cells with a tremendous reliance on mitochondrial capacity , and altered mitochondrial function can lead to heart failure [11–13], a common consequence of cardiomyopathy. Considering the importance of healthy mitochondrial function in cardiomyocyte homeostasis, a valuable area of study is to elucidate the factors that mediate altered heart mitochondrial physiology and its effects with cigarette smoke exposure. Previous studies have observed that cigarette smoke exposure inhibits mitochondrial respiratory function in blood cells  and myocardium , but a mediating mechanism has yet to be identified.
Cigarette smoke has long been known to robustly activate inflammatory pathways in the lung , which increases ceramide biosynthesis [17, 18]. Importantly, ceramides are known to disrupt mitochondrial structure and function [19, 20], possibly increasing risk of cardiomyopathy . Thus, the purpose of these studies was to determine whether the sphingolipid ceramide mediates cardiomyocyte mitochondrial disruption with cigarette smoke exposure. Considering the lung’s apposition with the environment, the lung is a logical site of external pathogen-induced stress, a product of which is ceramide biosynthesis . Moreover, given the heart’s location relative to pulmonary blood flow, the heart is a reasonable site of lung-derived ceramide uptake.
Cigarette smoke extract (CSE) was generated as previously described with slight modifications . Briefly, one 2RF4 research cigarette (University of Kentucky, Lexington, KY) was continuously smoked by connecting the filtered end of the cigarette to a vacuum pump, pulling the particles into 5 ml of DMEM/F12 and the resulting medium was defined as 100% CSE. The total particulate matter content of 2RF4 cigarettes is 11.7 mg/cigarette, tar is 9.7 mg/cigarette, and nicotine is 0.85 mg/cigarette. Dilutions were made using DMEM/F12 + 10% FBS. Human type II–like pulmonary adenocarcinoma cells (A-549; passage 10-15) were maintained in DMEM/F12 supplemented with 10% FBS (Invitrogen) and antibiotics. Cells were split into 6-well dishes and grown to 80% confluence. H9C2 cardiomyocytes were maintained in DMEM +10% FBS. For differentiation into myotubes, cells were grown to confluency and the medium was replaced with DMEM +10% horse serum (Invitrogen, Grand Island, NY). Myotubes were used for experiments on day 3 of differentiation. A-549 cultures were exposed to media supplemented with 10% CSE or media alone for 4 h, after which the medium was transferred to differentiated H9C2 cardiomyocytes (termed “conditioned medium”) for 12 h. Where indicated, cells were treated with myriocin (10 μM, Sigma, M1177), a known and widely used inhibitor of ceramide biosynthesis. Muscle cells were harvested for RNA, protein, and lipid isolation following treatments. Cell survival during treatments was confirmed by trypan blue exclusion.
Male C57Bl6 mice were housed in a conventional animal house and maintained on a 12-hour light–dark cycle. Two animal studies were conducted. In the first study, animals received standard diet chow (Harlan Teklad 8604) and water ad libitum. At 12 wk of age, animals were randomly divided into room air and cigarette smoke (CS)-exposed groups. Mice were placed in soft restraints and connected to the exposure tower of a nose-only exposure system (InExpose System, Scireq, Canada). Animals were nasally exposed to sidestream CS generated by research cigarettes where a computer-controlled puff was generated every minute, leading to 10 min of CS exposure followed by 10 min of fresh air, repeated once. The CS-exposed group inhaled CS from two cigarettes per day for one week, at which point the dosage was increased to two cigarettes twice daily. Control animals were similarly handled and restrained in fresh air for the same duration. For the second study, 12-wk-old mice were separated into one of eight treatment groups for eight weeks. Each of the following groups were duplicated to have one group receive vehicle or myriocin injections (0.3 mg/kg) every other day for a total of eight groups: 1) control – standard diet chow, no smoke; 2) cigarette smoke exposure (two cigarettes, twice daily) with standard diet chow; 3) high-fat, high-sugar diet (Harlan Teklad 45F30S); 4) high-fat, high-sugar diet with cigarette smoke exposure. Tissues were harvested at the conclusion of the study period. Studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) at Brigham Young University.
For isolation of lipids, cell pellets or tissue were suspended in 900 μl ice-cold chloroform/methanol (1:2) and incubated for 15 minutes on ice, then briefly vortexed. Separation of aqueous and organic phases required addition of 400 μl of ice-cold water and 300 μl of ice-cold chloroform. The organic phase was collected into a fresh vial, and lipids were dried in a vacuum centrifuge (Eppendorf Concentrator Plus). Lipids were characterized and quantified using a shotgun lipidomics technique on a Thermo Scientific LTQ Orbitrap XL mass spectrometer. Evaporated lipid samples were re-suspended in a 2:1 chloroform: methanol Folch solution (200 μL). The re-suspended lipids were then combined with a modified 2:1:1.25 chloroform: methanol: isopropanol Bligh and Dyer solution (800 μL) with 15 mM ammonium acetate acting as an ionizing adduct. A 1.74 μM phosphatidylethanolamine, 1 μM C-17 ceramide, 1 μM tripalmitin internal standard cocktail (1 μL) was spiked into each sample for mass calibration and characterization data alignment. Samples were analyzed using a 2.5-minute mass-window scanning method in positive-ion mode at a resolution of 100,000 (FWHM at 400 m/z) for all primary MS1 scans. MS2 fragmentation data was also collected (PQD at relative intensity of 35) and manually verified for each mass window to give additional confidence to the correct identification of abundant lipid species. Three technical replicate mass spectrometer runs were performed on each sample. Samples were injected at 8 μL/min using a direct-inject electrospray ionization (ESI) soft-ionization spray head from a Hamilton GASTIGHT glass syringe. A nitrogen sheath gas spray flow rate of 8 (arb. Units) was used for all runs. The spray voltage and capillary temperature were maintained at 5.0 KV and 275°C respectively. Each technical replicate was run in random order to reduce systematic bias. Data were analyzed using in-house developed peak summarization, recalibration, and lipid identification software using lipid database information from the LIPID Metabolites and Pathways Strategy (Lipid MAPS) Lipidomics Gateway database . To ensure high-confidence identifications, an intensity threshold estimated to be 5% above instrumental static signal was implemented. Lipid identities were only assigned when significantly observable peaks were identified in at least two of the three technical replicate runs. Non-zero lipid quantities were averaged from the replicate runs. The lipid species identified across different ionization states or with adducts were totaled together. Quantification was completed by normalizing total ion counts to the relative abundance of the internal standard that was spiked into each sample.
Cell and myocardium permeabilization
For cells, H9C2 cardiomyocytes were detached in culture dishes with 0.05% trypsin-EDTA (Sigma) and growth medium was added to the culture. Contents were transferred to a tube and centrifuged for 10 min at 1000 × g at RT. After removal of supernatant, cells were lifted in MiR05 [0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM sucrose, and g/l BSA (Sigma; A3803) adjusted to pH 7.1] plus 1 mg/ml digitonin and gently rocked at RT for 5 min before centrifugation at 1000 × g for 5 min. After discarding supernatant, cells were then suspended in 2.2 ml warm MiR05 and transferred to chambers in the O2K (Oroboros Instruments, Innsbruck, Austria). Following respiration protocol (outlined below), cells were removed from the chambers and used for further analysis, including protein quantification. For myocardial mitochondrial respiration, left ventricle was quickly removed from euthanized mice and immediately placed in ice-cold buffer X (60 mM K-MES, 35 mM KCl, 7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 20 mM tuarine, 5.7 mM ATP, 15 mM PCr, 6.56 mM MgCl2-6H2O, pH 7.1) and trimmed of connective tissue. Small fiber bundles were prepared and gently separated along their longitudinal axis under a surgical scope (Olympus, ST) to 1-2 mg. Bundles were then transferred to a tube with chilled buffer X and 50 μg/ml saponin and rocked at 4°C for 30 min, then washed in buffer Z (105 mM K-MES, 30 mM KCl, 10 mM KH2PO4, 5 mM MgCl2-6H2O, 0.5 mg/ml BSA, pH 7.1) at 4°C for at least 15 min. Samples were then blotted dry and weighed.
To isolate mitochondria from left ventricle myocardium, the whole heart was placed in isolation buffer (300 mM sucrose, 10 mM Na-HEPES, 0.2 mM EDTA, pH 7.2) and the left ventricle isolated. After finely mincing the sample, trypsin (Sigma T9935) was added for two minutes before adding trypsin inhibitor (Sigma T9003). The sample was then transferred to a conical tube and allowed to settle. After removal of supernatant, samples were resuspended in isolation buffer with BSA (Sigma A3803) and homogenized with Teflon pestle before centrifugation (600 × g for 10 min at 4°C). Supernatant was then transferred to a new tube and centrifuged (8000 × g for 15 min at 4°C), then washed by gently adding isolation buffer and rotating the tube. A portion of this suspension is used for protein quantification. The pellet was then resuspended with isolation buffer + BSA.
Mitochondrial respiration protocol
High-resolution O2 consumption was determined at 37°C in permeabilized cells and fiber bundles using the Oroboros O2K Oxygraph with MiR05 respiration buffer. Before addition of sample into respiration chambers, a baseline respiration rate was determined. After addition of sample, the chambers were hyperoxygenated to ~350 nmol/ml. Following this, respiration was determined by all or parts of the following substrate-uncoupler-inhibitor-titration (SUIT) protocol : electron flow through complex I was supported by glutamate + malate (10 and 2 mM, respectively) to determine basal oxygen consumption (GM B ). Following stabilization, ADP (2.5 mM) was added to determine oxidative phosphorylation capacity (GM P ). Succinate was added (GMS P ) for complex I + II electron flow into the Q-junction. To determine full electron transport system (F) capacity over oxidative phosphorylation, the chemical uncoupler carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) was added (0.05 μM, followed by 0.025 μM steps until maximal O2 flux was reached). Complex II-supported ETS was then measured by inhibiting complex I with rotenone (Rot; 0.5 μM). Mitochondrial membrane integrity was tested in all experiments by adding cytochrome c (10 μM; GMc P ). Lastly, residual oxygen consumption was measured by adding antimycin A (2.5 μM) to block complex III action, effectively stopping any electron flow, which provides a baseline rate of respiration. Where indicated, C2-ceramide (Sigma A7191; 20 μM) was added to respiration chambers.
Data are presented as the mean ± SEM. Data were compared by ANOVA with Tukey’s post-hoc analysis (Graphpad Prism; La Jolla, CA). Significance was set at p <0.05.
Ceramide inhibits cardiomyocyte mitochondrial respiration
Cigarette smoke extract increases lung cell ceramide production and secretion
Ceramide is necessary for smoke extract-induced altered cardiomyocyte mitochondrial disruption
Ceramide inhibition prevents reduced myocardial mitochondrial respiration with cigarette smoke
Previous research demonstrated that smoke exposure contributes to cardiomyopathy [27, 28], which can be a consequence of altered mitochondrial function , and we have recently shown that sidestream smoke alters mitochondrial function in skeletal muscle . Considering current worldwide smoking trends [3, 4], cardiomyopathy and other cardiovascular burdens mediated by cigarette smoke are likely to increase. To date, the main instigators thought to mediate the heart-specific effects of smoking are altered blood lipids and changes in fibrinogen metabolism, [30, 31], though the actual impact of these mechanisms is unknown . While ceramides are known to mediate cellular disruption in the lung with smoking , its impact on cardiomyocyte function with smoking has not been adequately explored. Thus, the purpose of this project was to determine the role of tobacco smoke-induced ceramides in disrupting cardiomyocyte mitochondrial function. Our major discoveries were that lung cells secrete ceramide with sidestream smoke exposure and that ceramide accumulates in heart tissue and alters mitochondrial function.
To our knowledge, the first study to explore the effects of ceramide on mitochondrial respiration was published by the Hoppel laboratory, where they observed a rapid and robust inhibition of respiration in isolated heart mitochondria upon ceramide treatment , and subsequent work corroborates these findings . We confirm those observations by Gudz et al.  in isolated heart mitochondria and report similar findings in permeabilized left ventricle. Additionally, we have previously shown that ceramides substantially inhibit complex II action and that the general adverse effect of ceramides on mitochondrial respiration is dependent on ceramide-induced mitochondrial fission . Similarly, our findings of ceramide accrual in the lung with smoking corroborate those from other laboratories [34–36], but while previous work focused on ceramide generation via sphingomyelinase, our effective use of myriocin suggests the importance of de novo ceramide synthesis in sidestream smoke-induced ceramide accumulation. However, while myriocin injections were sufficient to completely block ceramide accrual with smoking or diet separately, it was insufficient to prevent an increase in ceramides with combined smoking and diet. This may be a result of insufficient myriocin action in the midst of an overpowering stimulus (diet and smoke combined), or that sphingomyelinase may be particularly relevant in our combined treatment.
Importantly, we not only find increased ceramide production in lung cells with smoke exposure, but also ceramide release, providing proof of concept that the lung may be at least a source of systemic ceramide accrual with smoke exposure. This is supported by our finding of an upward trend in circulating ceramides with smoke exposure. Nonetheless, ongoing experiments are testing the hypothesis that secreted ceramide by smoke-exposed pulmonary tissues travel and accumulate in cardiac muscle. Related to this, our conclusions that ceramide is the relevant component within the cultured medium upon transfer of medium from lung cells to cardiomyocytes is based on our use of myriocin. However, due to the harmful cocktail of molecules within the CSE, it is possible that a non-ceramide variable exists.
The level of ceramide accumulation we observe in the heart with smoking is substantial. We have previously quantified ceramide in various tissues (i.e., skeletal muscle, liver, brain) with dietary intervention [17, 24, 37] and rarely observed greater than a roughly twofold increase in ceramides; similar changes have been observed in the heart . However, cigarette smoking appears to be a more robust inducer of systemic ceramide accumulation compared with diet. We found a roughly four-fold increase in heart ceramides after only 1 wk of smoke exposure (Figure 4) that increased to a six-fold change with an 8-wk exposure (Figure 4A). Interestingly, supplementing the smoking regimen with a dietary component (Western diet, Harlan Teklad 45F30S) had no additive effect on heart ceramides (Figure 5A).
In conjunction with our recent findings of altered skeletal muscle function with cigarette smoke exposure , the results of these studies implicate ceramide as an important mediator of myriad systemic metabolic effects. In particular, we find evidence that ceramides are a mediator of sidestream smoke-induced altered heart mitochondrial function. While interventions to promote smoking cessation should continue, the increase in worldwide smoking and cardiovascular complications highlights the need for immediate therapies. Our findings suggest that ceramide inhibition may be a novel and potentially valuable therapeutic modality to protect heart function for those who are unwilling or unable to vacate smoke environments.
- WHO urges more countries to require large, graphic health warnings on tobacco packaging: the WHO report on the global tobacco epidemic, 2011 examines anti-tobacco mass-media campaigns. Cent Eur J Public Health. 2011, 19: 133-151.Google Scholar
- Deitel M: Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg. 2003, 13: 329-330. 10.1381/096089203765887598.View ArticlePubMedGoogle Scholar
- Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, Wollum A, Sanman E, Wulf S, Lopez AD, Murray CJL, Gakidou E: Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014, 311: 183-192. 10.1001/jama.2013.284692.View ArticlePubMedGoogle Scholar
- Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Substance Abuse and Mental Health Services Administration. 2011Google Scholar
- Pirkle JL, Flegal KM, Bernert JT, Brody DJ, Etzel RA, Maurer KR: Exposure of the US population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988 to 1991. JAMA. 1996, 275: 1233-1240. 10.1001/jama.1996.03530400021033.View ArticlePubMedGoogle Scholar
- Pirkle JL, Bernert JT, Caudill SP, Sosnoff CS, Pechacek TF: Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988–2002. Environ Health Perspect. 2006, 114: 853-858. 10.1289/ehp.8850.View ArticlePubMedPubMed CentralGoogle Scholar
- Vital signs: nonsmokers' exposure to secondhand smoke - United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2010, 59: 1141-1146.Google Scholar
- Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008, 57: 1226-1228.Google Scholar
- Lakier JB: Smoking and cardiovascular disease. Am J Med. 1992, 93: 8S-12S. 10.1016/0002-9343(92)90620-Q.View ArticlePubMedGoogle Scholar
- Lopaschuk GD, Jaswal JS: Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol. 2010, 56: 130-140. 10.1097/FJC.0b013e3181e74a14.View ArticlePubMedGoogle Scholar
- Winter SC, Buist NR: Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine. Am Heart J. 2000, 139: S63-69. 10.1067/mhj.2000.103935.View ArticlePubMedGoogle Scholar
- Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M: Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J. 2003, 24: 280-288.View ArticlePubMedGoogle Scholar
- Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL: Mitochondrial dysfunction in cardiac disease: ischemia–reperfusion, aging, and heart failure. J Mol Cell Cardiol. 2001, 33: 1065-1089. 10.1006/jmcc.2001.1378.View ArticlePubMedGoogle Scholar
- Miro O, Alonso JR, Jarreta D, Casademont J, Urbano-Marquez A, Cardellach F: Smoking disturbs mitochondrial respiratory chain function and enhances lipid peroxidation on human circulating lymphocytes. Carcinogenesis. 1999, 20: 1331-1336. 10.1093/carcin/20.7.1331.View ArticlePubMedGoogle Scholar
- Knight-Lozano CA, Young CG, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, Ischiropoulos H, Ballinger SW: Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002, 105: 849-854. 10.1161/hc0702.103977.View ArticlePubMedGoogle Scholar
- Reynolds PR, Schmitt RE, Kasteler SD, Sturrock A, Sanders K, Bierhaus A, Nawroth PP, Paine R, Hoidal JR: Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol. 2010, 42: 545-551. 10.1165/rcmb.2008-0265OC.View ArticlePubMedGoogle Scholar
- Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA: Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011, 121: 1858-1870. 10.1172/JCI43378.View ArticlePubMedPubMed CentralGoogle Scholar
- Bikman BT: A role for sphingolipids in the pathophysiology of obesity-induced inflammation. CMLS. 2012, 69: 2135-2146. 10.1007/s00018-012-0917-5.View ArticlePubMedGoogle Scholar
- Bikman BT, Summers SA: Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest. 2011, 121: 4222-4230. 10.1172/JCI57144.View ArticlePubMedPubMed CentralGoogle Scholar
- Gudz TI, Tserng KY, Hoppel CL: Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem. 1997, 272: 24154-24158. 10.1074/jbc.272.39.24154.View ArticlePubMedGoogle Scholar
- Marin-Garcia J, Goldenthal MJ, Pierpont ME, Ananthakrishnan R: Impaired mitochondrial function in idiopathic dilated cardiomyopathy: biochemical and molecular analysis. J Card Fail. 1995, 1: 285-291. 10.1016/1071-9164(95)90003-9.View ArticlePubMedGoogle Scholar
- Reynolds PR, Cosio MG, Hoidal JR: Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells. Am J Respir Cell Mol Biol. 2006, 35: 314-319. 10.1165/rcmb.2005-0428OC.View ArticlePubMedPubMed CentralGoogle Scholar
- Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, Spener F, van Meer G, Wakelam MJ, Dennis EA: Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res. 2009, 50 (Suppl): S9-14.PubMedPubMed CentralGoogle Scholar
- Smith ME, Tippetts TS, Brassfield ES, Tucker BJ, Ockey A, Swensen AC, Anthonymuthu TS, Washburn TD, Kane DA, Prince JT, Bikman BT: Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle. Biochem J. 2013, 456: 427-439. 10.1042/BJ20130807.View ArticlePubMedGoogle Scholar
- Wilson CR, Tran MK, Salazar KL, Young ME, Taegtmeyer H: Western diet, but not high fat diet, causes derangements of fatty acid metabolism and contractile dysfunction in the heart of Wistar rats. Biochem J. 2007, 406: 457-467. 10.1042/BJ20070392.View ArticlePubMedPubMed CentralGoogle Scholar
- Baranowski M, Blachnio A, Zabielski P, Gorski J: PPARalpha agonist induces the accumulation of ceramide in the heart of rats fed high-fat diet. J Physiol Pharmacol. 2007, 58: 57-72.PubMedGoogle Scholar
- Gvozdjakova A, Bada V, Sany L, Kucharska J, Kruty F, Bozek P, Trstansky L, Gvozdjak J: Smoke cardiomyopathy: disturbance of oxidative processes in myocardial mitochondria. Cardiovasc Res. 1984, 18: 229-232. 10.1093/cvr/18.4.229.View ArticlePubMedGoogle Scholar
- Lough J: Cardiomyopathy produced by cigarette smoke. Ultrastructural observations in guinea pigs. Arch Pathol Lab Med. 1978, 102: 377-380.PubMedGoogle Scholar
- Thatcher MO, Tippetts TS, Nelson MB, Swensen AC, Winden DR, Hansen ME, Anderson MC, Johnson IE, Porter JP, Prince JT, Reynolds PR, Bikman BT: Ceramides mediate cigarette smoke-induced metabolic disruption in mice. Am J Physiol Endocrinol Metab. 2014Google Scholar
- Cullen P, Schulte H, Assmann G: Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM). Eur Heart J. 1998, 19: 1632-1641. 10.1053/euhj.1998.1086.View ArticlePubMedGoogle Scholar
- Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ: Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999, 99: 1411-1415. 10.1161/01.CIR.99.11.1411.View ArticlePubMedGoogle Scholar
- Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM: Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med. 2005, 11: 491-498. 10.1038/nm1238.View ArticlePubMedPubMed CentralGoogle Scholar
- Novgorodov SA, Gudz TI: Ceramide and mitochondria in ischemia/reperfusion. J Cardiovasc Pharmacol. 2009, 53: 198-208. 10.1097/FJC.0b013e31819b52d5.View ArticlePubMedPubMed CentralGoogle Scholar
- Schweitzer KS, Hatoum H, Brown MB, Gupta M, Justice MJ, Beteck B, Van Demark M, Gu Y, Presson RG, Hubbard WC, Petrache I: Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of oxidative stress and ceramides. Am J Physiol Lung Cell Mol Physiol. 2011, 301: L836-846. 10.1152/ajplung.00385.2010.View ArticlePubMedPubMed CentralGoogle Scholar
- Filosto S, Castillo S, Danielson A, Franzi L, Khan E, Kenyon N, Last J, Pinkerton K, Tuder R, Goldkorn T: Neutral sphingomyelinase 2: a novel target in cigarette smoke-induced apoptosis and lung injury. Am J Respir Cell Mol Biol. 2011, 44: 350-360. 10.1165/rcmb.2009-0422OC.View ArticlePubMedGoogle Scholar
- Levy M, Khan E, Careaga M, Goldkorn T: Neutral sphingomyelinase 2 is activated by cigarette smoke to augment ceramide-induced apoptosis in lung cell death. Am J Physiol Lung Cell Mol Physiol. 2009, 297: L125-133. 10.1152/ajplung.00031.2009.View ArticlePubMedPubMed CentralGoogle Scholar
- Bikman BT, Guan Y, Shui G, Siddique MM, Holland WL, Kim JY, Fabrias G, Wenk MR, Summers SA: Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis. J Biol Chem. 2012, 287: 17426-17437. 10.1074/jbc.M112.359950.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/14/165/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.